URGN - Company ID 0001668243
The table below shows UroGen Pharma Ltd.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $109.79M | $90.40M | $82.71M | $64.36M | $48.04M | $11.80M |
| Cost of revenue | $12.45M | $8.88M | $9.36M | $7.65M | $5.16M | $1.01M |
| Gross profit | $97.34M | $81.52M | $73.35M | $56.70M | $42.88M | $10.79M |
| R&D | $67.11M | $57.15M | $45.61M | $52.91M | $47.64M | $47.31M |
UroGen Pharma Ltd. reported annual revenue of $109.79M for fiscal year 2025. That is up 21.4% from $90.40M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $17.53M (FY 2016) to $109.79M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $155.10M |
| $121.15M |
| $93.27M |
| $82.84M |
| $87.53M |
| $90.22M |
| Operating income | -$124.86M | -$96.78M | -$65.54M | -$79.04M | -$92.29M | -$126.74M |
| Income tax | $78.00K | $2.83M | $3.92M | $1.75M | $1.45M | $3.37M |
| Net income | -$153.49M | -$126.87M | -$102.24M | -$109.78M | -$110.82M | -$128.48M |
| EPS (diluted) | - | - | - | - | - | - |